Corporate Spotlight

ZIRCON Presentation at International Kidney Cancer Symposium 2021

8 November 2021 – Corporate Spotlight | Telix presents Phase III ZIRCON trial at the International Kidney Cancer Symposium 2021

Telix is pleased to release a poster on the Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab), the Company’s investigational imaging agent for clear cell renal cell carcinoma (ccRCC) with positron emission tomography (PET), presented at the International Kidney Cancer Symposium (IKCS) 2021, organized by the Kidney Cancer Association.

The poster was presented by Dr. Allan Pantuck, Principal Investigator at the University of California, Los Angeles, one of the clinical sites for the global ZIRCON trial.

 

TLX250-CDx, Multi-Center Phase III Trial for PET/CT Imaging of Clear Cell Kidney Cancer 

ZIRCON Poster at IKCS

Authors: Brian Shuch1, Allan Pantuck 1, and Colin Hayward2
1Department of Urology, University of California at Los Angeles, Los Angeles, CA; 2 Telix Pharmaceuticals, Melbourne, Australia

 

TLX250-CDx has not received a marketing authorisation in any jurisdiction. 

To download the poster presentation in PDF please click here.

For more on Telix’s investigational kidney cancer program please click here.

To return to Telix’s homepage please click here.